scholarly journals PP032 Holistic Patient Access Processes Of Medical Devices In South Korea

2017 ◽  
Vol 33 (S1) ◽  
pp. 85-86
Author(s):  
Sang-Soo Lee ◽  
Moo Yeol Lee ◽  
Veronica Kim ◽  
Kyungja Lee ◽  
Young-Kwan Kwon

INTRODUCTION:Historically, patient access processes of new and innovative medical devices including in-vitro diagnostics are made in the sequence of regulatory approval, new Health Technology Assessment (nHTA) approval, reimbursement coverage and coding finally reaching the pricing approval stage in South Korea. Although the individual patient access process has its own distinct objective and perspective, there are still opportunities for the authorities or agencies in charge to streamline their processes by working together to promote earlier patient access of new and innovative medical devices to patients without impacting their own decision making.METHODS:This research examined and analyzed the current policies about: patient access processes with a holistic viewpoint, industry-wide survey about patient access practices; case studies of two innovative medical devices for patient access in South Korea and also proposed new or alternative programs which can contribute to patient access harmonization efforts with a holistic approach.RESULTS:Historically, health authorities play defensive strategies by delaying the adoption of new and innovative medical devices and implementing certain periods (that is, 2 to 5 years) for a patient's out-of-pocket payment scheme. It is well illustrated with the statistic that only twenty-nine percent of new and innovative medical technologies which have successfully gone through the nHTA process were determined for reimbursement coverage in the past 7 years.The survey by the medical device industry to determine the patient access lead-time of innovative medical devices with a holistic perspective indicated significantly delayed patient access even considerabley exceeding the legally required decision-making lead time. The in-depth case studies with two innovative devices indicated the disadvantageous patient access processes to the innovator in terms of both final approval timing and the price level.CONCLUSIONS:The concurrent review process for reimbursement coverage decision making for medical procedures, medical devices and reimbursement coverage payment guidelines committed within the Health Insurance Review and Assessment Service shall be created. New programs to deal with uncertainty in reimbursement coverage decision making shall be considered such as coverage with evidence development, performance-based risk-sharing arrangement, multi-criteria decision analysis and economic evaluation.

2000 ◽  
Vol 02 (04) ◽  
pp. 453-476 ◽  
Author(s):  
ERICA ISON ◽  
ANNE MILLER

In the NHS, criteria for the selection and purchase of medical devices tend to be restricted to concerns about any risks to patients and/or staff during clinical practice, and the purchase price. In addition, the basis for taking many of these decisions about purchase may be only that of personal opinion, anecdote or limited information. We report on the application of life-cycle assessment (LCA) to a particular medical device — the suction receptacle — as a case-study to determine the potential of LCA to improve the range and quality of information available for decision-making, and act as a framework for a more holistic approach. Using LCA, substantial environmental and economic burdens were found to be associated with the different product systems in use (durable versus disposable devices). We discuss the ways in which various stakeholders in the healthcare sector could use this information, at both a strategic and operational level. We also outline possible future developments of LCA that would support healthcare managers in the drive towards evidence-based decision-making.


2019 ◽  
Vol 35 (03) ◽  
pp. 229-236
Author(s):  
Sang-Soo Lee ◽  
Jae-Eun Myung ◽  
Liesl Strachan

AbstractBackground and ObjectivesTimely access to innovative medical technologies driven by accelerated patient access pathways can substantially improve the health outcomes of patients who often have few therapeutic alternatives. We analyzed lead-times for the medical procedure reimbursement coverage process undertaken in South Korea from 2014 to 2017, which is considered one of the most important factors contributing to delays in patient access to new medical technologies.MethodsThis analysis was performed using the open datasets source of “Medical Procedure Expert Evaluation Committee (MPEEC)” meeting results and medical procedure coverage application information published on the Health Insurance Review and Assessment Service Web site.ResultsFrom 2014 to 2017, 90 percent of all new coverage determinations took on average >250 days with almost 20 percent taking more than 2 years (>750 days), The average lead-time from the medical procedure coverage application to MPEEC meeting in 2015 was 435.0 ± 214.7 days (n= 26), which was significantly shorter than the average lead-time in 2014 (624.9 ± 290.3 days,n= 16) (p< .05). The average lead-time from application to official enforcement in 2015 was significantly shorter than that of 2014 (540.8 ± 217.4; n = 16 versus 734.1 ± 299.7 days;n= 26, respectively) (p< .05).ConclusionsWhile this analysis showed a general trend of a reduction in the time taken to receive a positive coverage determination for a new medical technology, the average lead-time remains well over the government mandated 100 days. To continue this trend and further enhance the patient access pathway for medical procedure coverage determinations, some measures can be applied. In particular, the extended “One-Stop Service” program encompassing coverage determinations is one such recommendation that could be considered.


PLoS ONE ◽  
2018 ◽  
Vol 13 (10) ◽  
pp. e0206121
Author(s):  
Eun-Young Bae ◽  
Hui Jeong Kim ◽  
Hye-Jae Lee ◽  
Junho Jang ◽  
Seung Min Lee ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document